Hjem › Lungekreft › Colorado › Grand Junction
Kliniske studier for Lungekreft i Grand Junction, CO
4 studier for Lungekreft søker deltakere på steder i og rundt Grand Junction (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekruttererFase 3
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- Intermountain Health, Grand Junction
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Rekrutterer
- VA Western Colorado Health Care System, Grand Junction
Improving Care for Rural Patients With Solid Tumors
Rekrutterer
- SCL- St. Mary's Medical Center, Grand Junction
- VA Western Colorado Health Care System, Grand Junction
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Arlington, VA41 studier
- Washington, DC41 studier
- Chicago, IL41 studier
- Baltimore, MD40 studier
- Nashville, TN40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Grand Junction
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.